EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 29 / Numéro 6-7 (Juin–Juillet 2013) Med Sci (Paris), 29 6-7 (2013) 607-616 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 6-7, Juin–Juillet 2013
Page(s) 607 - 616
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013296013
Publié en ligne 12 juillet 2013
  1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009 ; 34 : 1219–1263. [CrossRef] [PubMed] [Google Scholar]
  2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004 ; 351 : 1425–1436. [CrossRef] [PubMed] [Google Scholar]
  3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009 ; 54 : S43–S54. [CrossRef] [PubMed] [Google Scholar]
  4. Girerd B, Montani D, Eyries M, et al. Absence of influence of gender, BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010 ; 11 : 73. [CrossRef] [PubMed] [Google Scholar]
  5. O’Callaghan DS, Savale L, Montani D, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011 ; 8 : 526–538. [CrossRef] [PubMed] [Google Scholar]
  6. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010 ; 122 : 156–163. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  7. Perros F, Montani D, Dorfmuller P, et al. Nouvelles approches immunopathologiques de l’HTAP. Presse Med 2011 ; 40 Suppl 1 : 1S3–13. [CrossRef] [PubMed] [Google Scholar]
  8. Tamby MC, Chanseaud Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005 ; 60 : 765–772. [CrossRef] [PubMed] [Google Scholar]
  9. Terrier B, Tamby MC, Camoin L, et al. Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis 2010 ; 69 : 428–433. [CrossRef] [PubMed] [Google Scholar]
  10. Terrier B, Tamby MC, Camoin L, et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008 ; 177 : 1128–1134. [CrossRef] [PubMed] [Google Scholar]
  11. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008 ; 58 : 521–531. [CrossRef] [PubMed] [Google Scholar]
  12. Pugh ME, Hemnes AR. Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Womens Health (Lond Engl) 2010 ; 6 : 285–296. [CrossRef] [PubMed] [Google Scholar]
  13. Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, et al. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun 2012 ; 38 : J109–J119. [CrossRef] [PubMed] [Google Scholar]
  14. Larkin EK, Newman JH, Austin ED, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 ; 186 : 892–896. [CrossRef] [PubMed] [Google Scholar]
  15. Tofovic SP. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol 2010 ; 56 : 696–708. [CrossRef] [PubMed] [Google Scholar]
  16. Nicolls MR, Taraseviciene-Stewart L, Rai PR, et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005 ; 26 : 1110–1118. [CrossRef] [PubMed] [Google Scholar]
  17. Perros F, Dorfmuller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 ; 185 : 311–321. [CrossRef] [PubMed] [Google Scholar]
  18. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a french nationwide prospective multicenter study. Arthritis Rheum 2005 ; 52 : 3792–3800. [CrossRef] [PubMed] [Google Scholar]
  19. Fois E, Le Guern V, Dupuy A, et al. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. Clin Exp Rheumatol 2010 ; 28 : 836–841. [PubMed] [Google Scholar]
  20. Chu JW, Kao PN, Faul JL, et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002 ; 122 : 1668–1673. [CrossRef] [PubMed] [Google Scholar]
  21. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008 ; 177 : 108–113. [CrossRef] [PubMed] [Google Scholar]
  22. Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009 ; 119 : 1518–1523. [CrossRef] [PubMed] [Google Scholar]
  23. Austin ED, Rock MT, Mosse CA, et al. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir Med 2010 ; 104 : 454–462. [CrossRef] [PubMed] [Google Scholar]
  24. Ulrich S, Nicolls MR, Taraseviciene L, et al. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration 2008 ; 75 : 272–280. [CrossRef] [PubMed] [Google Scholar]
  25. Huertas A, Tu L, Gambaryan N, et al. Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J 2012 ; 40 : 895–904. [CrossRef] [PubMed] [Google Scholar]
  26. Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 ; 186 : 897–908. [CrossRef] [PubMed] [Google Scholar]
  27. Tamosiuniene R, Tian W, Dhillon G, et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res 2011 ; 109 : 867–879. [CrossRef] [PubMed] [Google Scholar]
  28. Perros F, Cohen-Kaminsky S, Humbert M. Understanding the role of CD4+CD25(high) (so-called regulatory) T cells in idiopathic pulmonary arterial hypertension. Respiration 2008 ; 75 : 253–256. [CrossRef] [PubMed] [Google Scholar]
  29. Karmochkine M, Cacoub P, Dorent R, et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 1996 ; 23 : 286–290. [PubMed] [Google Scholar]
  30. Riboldi P, Gerosa M, Raschi E, et al. Endothelium as a target for antiphospholipid antibodies. Immunobiology 2003 ; 207 : 29–36. [CrossRef] [PubMed] [Google Scholar]
  31. Bussone G, Tamby MC, Calzas C, et al. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis 2012 ; 71 : 596–605. [CrossRef] [PubMed] [Google Scholar]
  32. Renaudineau Y, Dugue C, Dueymes M, et al. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002 ; 1 : 365–372. [CrossRef] [PubMed] [Google Scholar]
  33. Negi VS, Tripathy NK, Misra R, et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998 ; 25 : 462–466. [PubMed] [Google Scholar]
  34. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995 ; 151 : 1628–1631. [CrossRef] [PubMed] [Google Scholar]
  35. Farha S, Sharp J, Asosingh K, et al. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Pulm Circ 2012 ; 2 : 220–228. [CrossRef] [PubMed] [Google Scholar]
  36. Benoist C, Mathis D. Mast cells in autoimmune disease. Nature 2002 ; 420 : 875–878. [CrossRef] [PubMed] [Google Scholar]
  37. Arends SJ, Damoiseaux J, Duijvestijn A, et al. Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension. Eur Respir J 2010 ; 35 : 923–925. [CrossRef] [PubMed] [Google Scholar]
  38. Rose NR. Bona C Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today 1993 ; 14 : 426–430. [CrossRef] [PubMed] [Google Scholar]
  39. Yeager M, Cripe PJ, Colvin KL, et al. Loss of tolerance associated with bronchus associated lymphoid tissue expansion in pulmonary hypertension. Am J Respir Crit Care Med 2012 ; 185 : A4761. [Google Scholar]
  40. Quismorio FP, Jr, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984 ; 13 : 349–359. [CrossRef] [PubMed] [Google Scholar]
  41. Carragher DM, Rangel-Moreno J, Randall TD. Ectopic lymphoid tissues and local immunity. Semin Immun 2008 ; 20 : 26–42. [CrossRef] [Google Scholar]
  42. Price LC, Montani D, Tcherakian C, et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J 2011 ; 37 : 813–822. [CrossRef] [PubMed] [Google Scholar]
  43. Ogawa A, Nakamura K, Mizoguchi H, et al. Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011 ; 183 : 139–140. [CrossRef] [PubMed] [Google Scholar]
  44. Hennigan S, Channick RN, Silverman GJ. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus 2008 ; 17 : 754–756. [CrossRef] [PubMed] [Google Scholar]
  45. Semerano L, Boissier MC. Les anticorps monoclonaux dans les maladies immunes inflammatoires chroniques. Med Sci (Paris) 2009 ; 25 : 1108–1112. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  46. Tanaka Y. Diagnosis and therapy for systemic lupus erythematosus. Nihon Naika Gakkai Zasshi 2007 ; 96 : 2159–2164. [CrossRef] [PubMed] [Google Scholar]
  47. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005 ; 52 : 501–513. [CrossRef] [PubMed] [Google Scholar]
  48. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012 ; 33 : 571–577. [CrossRef] [PubMed] [Google Scholar]
  49. Kishimoto T. Interleukin-6 and its receptor in autoimmunity. J Autoimmun 1992 ; 5 Suppl A : 123–132. [CrossRef] [PubMed] [Google Scholar]
  50. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circulation Res 2009 ; 104 : 236–244. [Google Scholar]
  51. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010 ; 122 : 920–927. [CrossRef] [PubMed] [Google Scholar]
  52. Karavolias GK, Georgiadou P, Gkouziouta A, et al. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses. Expert Opin Ther Targets 2010 ; 14 : 1283–1289. [CrossRef] [PubMed] [Google Scholar]
  53. Furuya Y, Satoh T, Kuwana M., Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol 2010 ; 2010 : 720305. [PubMed] [Google Scholar]
  54. Arita Y, Sakata Y, Sudo T, et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman’s disease. Heart Vessels 2010 ; 25 : 444–447. [CrossRef] [PubMed] [Google Scholar]
  55. Taniguchi K, Shimazaki C, Fujimoto Y, et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman’s disease. Int J Hematol 2009 ; 90 : 99–102. [CrossRef] [PubMed] [Google Scholar]
  56. Terrier B, Mouthon L. Lupus érythémateux systémique. Med Sci (Paris) 2013 ; 29 : 65–73. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  57. Cartron G, Rossi JF. Anticorps monoclonaux thérapeutiques en oncohématologie. Med Sci (Paris) 2009 ; 25 : 1085–1089. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.